CCL22 and TGF-β1 expression in BC.

<p>(A) Negative expression of TGF-β1 in BC (×200). (B) Weak expression of TGF-β1 in BC (×200). (C) Strong expression of TGF-β1 in BC (×200). (D) Negative expression of CCL22 in BC (×200). (E) Weak expression of CCL22 in BC (×200). (F) Strong expression of CCL22 in BC (×200).</p

Prognostic significance of CCL22 Expression in BC.

<p>Kaplan–Meier curves of overall survival (OS) (A) and progression-free survival (PFS) (B) for CCL22 expression in BC to show the association of CCL22 expression with reduced OS (P<0.0001) and PFS (P<0.0001). P values were calculated by the log-rank test.</p

Expression of both CCL22 and Foxp3 ⁺Tregs infiltration in the tumor bed was associated with BC prognosis.

<p>Kaplan-Meier curves are shown for overall survival (OS) (A) and progression-free survival (PFS) (B) was stratified by expressions of two factors to divide the patients into three subsets, CCL22^-Foxp3^low+ group, CCL22^-Foxp3^high+/CCL22⁺Foxp3^low+ group, and CCL22⁺Foxp3^high+ group. The CCL22⁺Foxp3^high+ group was associated with both shorter OS (P=0.001) and PFS (P=0.001) than CCL22^-Foxp3^high+/CCL22⁺Foxp3^low+ group, and CCL22^-Foxp3^low+ group.</p